vda-1102
Small moleculeexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02844777)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vda-1102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03538951 | Phase 2 | May 23, 2018 | Icahn School of Medicine at Mount Sinai, Medistat Ltd., Israel, PharPoint Research, Inc., Therapeutics, Inc., Vidac Pharma |
| NCT02844777 | Phase 2 | Jul 1, 2016 | Vidac Pharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vidac Pharma | For profit | 2 | 2 | 1 | 2016 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Medistat Ltd., Israel | For profit | 1 | 0 | 1 | 2018 |
| PharPoint Research, Inc. | For profit | 1 | 0 | 1 | 2018 |
| Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1